[Form 4] Cytek Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

NACCO Industries, Inc. (NYSE: NC) filed a Form 4 reporting that non-employee director Valerie Gentile Sachs received 770 shares of the company’s Class A common stock on 07/01/2025. The shares were issued as “Required Shares” under the company’s Non-Employee Directors’ Equity Compensation Plan and are coded “A” for an acquisition that is not an open-market purchase. Following the grant, Sachs now directly owns 8,578 shares. No sales, option exercises, or derivative security transactions were disclosed, and the filing does not cite a Rule 10b5-1 trading plan. The report was signed by attorney-in-fact Matthew J. Dilluvio on 07/02/2025.

Insights

Securities Analyst

TL;DR: Routine director stock grant; immaterial impact on float or insider-sentiment.

The 770-share award represents an incremental ~0.01% of NACCO’s ~7.6 million Class A shares outstanding and raises Director Sachs’ direct stake to 8,578 shares (about 0.11% of the class). Because the grant is part of the standing equity compensation plan and not an open-market purchase, it offers limited signaling value regarding management’s outlook. No accompanying sales or derivative positions change the overall insider ownership profile. I classify the filing as neutral/not impactful for valuation or liquidity considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imper Vera

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		A		43,973		(2)	(2)	Common Stock	43,973	$0	43,973	D
Director Stock Option (right to buy)	$3.07	06/18/2025		A		23,809		(3)	06/18/2035	Common Stock	23,809	$0	23,809	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

3. 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

	/s/ Valerie Barnett, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NACCO (NC) shares did Director Valerie Gentile Sachs acquire on July 1, 2025?

She received 770 shares of Class A common stock.

What is Valerie Sachs’ total direct ownership in NC after the Form 4 transaction?

Her direct holdings increased to 8,578 shares.

Was the July 2025 share acquisition part of a Rule 10b5-1 trading plan?

The filing does not indicate that the transaction was made under a 10b5-1 plan.

Did the Form 4 report any sales or derivative security transactions?

No. The filing lists only an equity award; no sales or derivatives were disclosed.

What transaction code was used in the Form 4 for the share award?

Transaction code “A”, indicating an acquisition other than an open-market purchase.